Literature DB >> 18629573

Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines.

M Duyvendak1, M Naunton, E N van Roon, G A W Bruyn, J R B J Brouwers.   

Abstract

UNLABELLED: Corticosteroid-induced osteoporosis (CIOP) is currently undertreated. Systematic review of the literature revealed that the percentage of patients treated adequately is dependent on study quality. Therefore, it remains unknown whether adherence to the guidelines is really so poor. Five major quality criteria provide the standard for future studies on this scope.
INTRODUCTION: It has recently been stated that the degree of prophylaxis of corticosteroid-induced osteoporosis (CIOP) is low and effort should be put into determining reasons for non-prescribing of preventive agents. The aim of this study was to identify: how many studies adequately audit the prevalent guideline; the longitudinal trends in prevention of CIOP; which patient groups appear to be most undertreated; and which intervention strategies are effective.
METHODS: We performed a comprehensive search of MEDLINE and systematically recorded the outcomes and quality of published studies, using five major criteria.
RESULTS: Twenty-four studies were included in the analysis. The quality of the included studies was poor (31%) or moderate (37%). There was a longitudinal increase in quality of the studies and percentage of prevention. Multivariable linear regression showed that the quality of the study was the only independent predictor of the prevention rate reported in the study.
CONCLUSIONS: The results show undertreatment of CIOP might be due to insufficient quality of the studies rather than poor practice or failure to recognise the right patients. Future interventions should comply with five major quality criteria, and a multifaceted approach is required in order to make an impact on the underprescribing of CIOP prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18629573     DOI: 10.1007/s00198-008-0598-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  69 in total

1.  Myasthenia gravis, corticosteroids and osteoporosis prophylaxis.

Authors:  G D Smith; D L Stevens; G N Fuller
Journal:  J Neurol       Date:  2001-02       Impact factor: 4.849

2.  Osteoporosis prevention in myasthenia gravis: a reminder.

Authors:  S J Lewis; P E Smith
Journal:  Acta Neurol Scand       Date:  2001-05       Impact factor: 3.209

3.  Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.

Authors:  L J Walsh; C A Wong; M Pringle; A E Tattersfield
Journal:  BMJ       Date:  1996-08-10

4.  Prevention of corticosteroid induced osteoporosis in inpatients recently discharged from a tertiary teaching hospital.

Authors:  M D Smith; S P Cheah; K Taylor; M J Ahern
Journal:  J Rheumatol       Date:  2001-03       Impact factor: 4.666

5.  Compliance with osteoporosis medications.

Authors:  Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart
Journal:  Arch Intern Med       Date:  2005-11-14

6.  Osteoporosis Clinical Guideline. South African Medical Association--Osteoporosis Working Group.

Authors:  S Hough
Journal:  S Afr Med J       Date:  2000-09

7.  Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.

Authors:  B Gudbjornsson; U I Juliusson; F V Gudjonsson
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

8.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

9.  Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.

Authors:  J Adachi; A Cranney; C H Goldsmith; W G Bensen; F Bianchi; A Cividino; G L Craig; E Kaminska; R J Sebaldt; A Papaioannou
Journal:  J Rheumatol       Date:  1994-10       Impact factor: 4.666

10.  Steroid induced osteoporosis: an opportunity for prevention?

Authors:  I D Peat; S Healy; D M Reid; S H Ralston
Journal:  Ann Rheum Dis       Date:  1995-01       Impact factor: 19.103

View more
  1 in total

1.  Effect of transforaminal epidural polydeoxyribonucleotide injections on lumbosacral radiculopathy: A case report.

Authors:  Keum Nae Kang; Tae Woong Kim; Jin Woo Koh; Han Byeol Oh; Jong-Uk Mun; Mi Sook Seo; Young Uk Kim
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.